Two clinical trials of Merck’s pulmonary arterial hypertension drug Winrevair were so conclusive that the studies were halted because the efficacy of the treatment was assured. Now, Merck has reported results from the phase 3 Hyperion study, which showed that Winrevair reduced the risk of clinical worsening events by 76% in recently diagnosed adults.
